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with the details of individual relationships to provide a complete view of the system.
Because many of the chapters were previously published in other books and journals,
some seem out ofcontext; however, chapters original to the book serve to integrate the
different studies and ameliorate this problem.
Dissatisfaction among physicians practicing medicine is becoming nearly ubiqui-
tous. Many of these problems stem from the lack of autonomy experienced by many
physicians as a result ofincreasing budgetary constraints. Ifphysicians are to continue
to derive pleasure from their work and to preserve thequality ofhealth care, they must
become actively involved in shaping health care policies-but discussion of personal
experience is notenough. Without a languageand theoretical framework toexplain the
dilemma, including its possible negative repercussions for patients and physicians
alike, those making policy will continue to regard monetary issues as more urgent. This
book provides one sociologist's view ofthe system and his proposals for reforms and is
an excellent place tobegin to formulateone's own ideas about future health carepolicy.
ELLEN M. SMITH
Department ofPsychiatry
Yale UniversitySchoolofMedicine
RETROVIRUS BIOLOGY AND HUMAN DISEASE. Edited by Robert C. Gallo and Flossie
Wong-Staal. New York, Marcel Dekker, Inc., 1990. 432 pp. $99.75.
Substantial progress has been made in understanding retrovirus biology since the
discovery ofthe first human retrovirus, HTLV-I, in 1979. The body ofknowledge that
has accrued in the field of animal retrovirology has provided researchers with the
momentum necessary for the rapid advances in human retrovirology today.
Retrovirus Biology and Human Disease, edited by Robert C. Gallo and Flossie
Wong-Staal, is a comprehensive critique of the research to date on retroviruses. The
chapters attempt to integrate a vast array of knowledge from the earliest studies of
retroviruses in bovine, feline, and ruminant animals to the latest research and technol-
ogy in human HTLVs.
The first chapter begins with an introduction from a concise but comprehensive
historical perspective by Gallo and NIH colleague Marvin S. Reitz. It traces the
earliest findings linking retroviruses with leukemia in mammals to the isolation of
HTLV-I, the first human retrovirus from T-cell lymphoma/leukemia patients, and
finally to the current state ofknowledge about HTLV-II, HIV-2, HIV-3, and HIV-4.
The book devotes several chapters to the development and understanding ofretrovi-
rus processes in bovine leukemia and feline leukemia, as well as a comprehensive
section on biology and pathogenesis of lentiviruses. The two chapters devoted to
HTLV-I provide a complete and detailed analysis of clinical, epidemiological, and
molecular aspects of adult T-cell leukemia. Clinicians will appreciate the well-
balanced treatment of disease, therapy, and diagnosis. Basic researchers should find
the chapter on molecular biology of HTLV-I, with its detailed coverage of trans-
activating factors, pX gene products, and IL-2R gene activation both useful and
informative. The final seven chapters attempt to integrate the latest information on
HTLV-II and AIDS from a clinical, molecular, and epidemiological perspective.
While this book is designed to inform the basic science community of the latest
progress in retrovirus research, several chapters could be recommended for those
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boast authors who are experts in their fields, stand alone as comprehensive critiques of
the current technology or as organized, well-integrated sections of the complete
retrovirus body ofliterature.
Clinicians and basic researchers will appreciate the well-balanced coverage of
disease and molecular processes, the clear prose, the concise summaries, and, finally,
the comprehensive citation ofreferences at the end ofeach chapter. The only difficulty
with such a contemporary treatment is that much of the current data on HIV has
already become dated by the time of the book's publication. The volume is, however,
recommended for all those who wish to supplement their knowledge of retroviruses
whether it be from a current or historical perspective, particularly those who need a
valuable, readily readable resource for later reference.
MAY C. CHEN
MedicalStudent
Yale UniverstiySchoolofMedicine
ACYCLOVIR THERAPY FOR HERPESVIRUS INFECTIONS. Edited by David A. Baker. New
York, Marcel Dekker, Inc., 1990. 323 pp. $99.75.
This multi-authored text, composed of 17 chapters relating to the antiviral agent
acyclovir (ACV), is the fourth volume of a series, Infectious Disease and Therapy,
edited by B.E. Scully and H.C. Neu. ACV [9-(2-hydroxyethoxymethyl) guanine] is a
synthetic nucleoside analogue with considerable antiviral activity against members of
the Herpesvirus group.
Acyclovir was introduced in 1982 as a topical agent and in 1983 for intravenous use.
Like other antiviral agents, as well as anti-cancer agents, its use relies on the principle
of "selective toxicity." In other words, the drug is active against the virus in the
infected cell, and the adjacent normal cells are spared drug toxicity. This agent is more
virus-specific than previously available antivirals because it is activated mainly by a
virus-specific thymidine kinase and then acts as an inhibitor of a viral DNA poly-
merase. Its lack of systemic toxicity in the host has resulted in a leap forward in the
treatment of infections due to herpes simplex virus (HSV) and varicella zoster virus
(VZV). (It is less effective against Epstein-Barr virus [EBV] and not useful for
cytomegalovirus [CMV] infections.) The importance of infections due to these viral
agents and the fact that acyclovir has become the drug of choice make this book a
reasonable resource for a clinical infectious disease specialist.
The book contains background chapters on the molecular biology, toxicity, and
pharmacology of ACV. The bulk of the volume is therapy-oriented and arranged by
specific viral agents and herpesvirus-caused diseases. There is appropriate emphasis
throughout on the immunocompromised host. These chapters are written by clinical
research specialists, each ofwhom is recognized as having authored the major clinical
studies in the field. Having Whitley write on HSV, Feldman on VZV, Arvin on
pediatric pharmacology, and Straus on EBV means that the text includes truly
authoritative reviews on the clinical studies of ACV use. Each of these chapters
provides a comprehensive review ofpublished studies. The twochaptersco-authored by
Richard Whitley, one on HSV encephalitis and the other on neonatal HSV infections,
are outstanding and carefully synthesize material from dozens of studies. Other
chapters on the useofACV in pregnancy, in infections ofthe eye, and in genital herpes
provide specialized information not available in general reviews ofthe drug.